Dabigatran: how the drug company withheld important analyses.
نویسنده
چکیده
منابع مشابه
Dabigatran etexilate - A novel oral anticoagulant for bleeding complications
Thromboembolic disease is a common cause of morbidity and mortality. Thrombin plays a key role in thrombotic events and thrombin inhibition represents a therapeutic event for thromboembolic events and has been identified as a target of therapy of its pivotal role in coagulation process. Anticoagulation is a major intervention for the management of arterial and venous thromboembolic events. Dabi...
متن کاملConservative Management of Dabigatran Overdose: Case Report and Review of Literature
Background: Direct thrombin inhibitors and factor Xa inhibitors are gaining popularity as alternatives to warfarin for patients requiring anticoagulation. Toxicity due to these medications is difficult to manage because overdose experience is very limited and there is no clear guidance on when or whether to use antidote in this setting. Case Presentation: A 50-year-old man with normal renal fu...
متن کاملCardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment
BACKGROUND Dabigatran 150 mg twice daily was shown to be superior to warfarin in preventing stroke in subjects with nonvalvular atrial fibrillation (SPAF) in the RE-LY (Randomized Evaluation of Long-term anticoagulation therapY) trial. Numerically, more myocardial infarctions occurred in patients receiving dabigatran compared with well-controlled warfarin. This observation prompted a comprehens...
متن کاملConcerns over data in key dabigatran trial.
One of the key selling points of the new oral anticoagulant dabigatran for use in stroke prevention in non-valvular atrial fibrillation is that the drug requires no time consuming anticoagulant activity or drug plasma level monitoring. But the evidence on which these claims were based has been called into question by the publication of new material as a result of an investigation in The BMJ. Do...
متن کاملDrug name alert: potential for confusion between pradax and plavix.
In this article, the authors highlight an incident that involved a mix-up between the oral anticoagulant medication Pradax (dabigatran etexilate) and the antiplatelet medication Plavix (clopidogrel). Because critical care nurses may admit or care for patients who are receiving (or have received) one of these medications, it is important that they be aware of the potential for confusion between ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- BMJ
دوره 349 شماره
صفحات -
تاریخ انتشار 2014